When stratified by PDE10A mRNA levels, PDE10AHIGH expressing ovarian cancer patients exhibited significantly worse overall survival (22 months) in comparison to those with low (44 months; p = 0.0006) or medium PDE10A expression (45 months; p = 0.0041) (Fig. 1A). This evidence concerns the gene PDE10A and ovarian carcinoma.